Last reviewed · How we verify

Chong Kun Dang Pharmaceutical — Portfolio Competitive Intelligence Brief

Chong Kun Dang Pharmaceutical pipeline: 24 marketed, 0 filed, 56 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

24 marketed 0 filed 56 Phase 3 6 Phase 2 142 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
tacrolimus capsules tacrolimus capsules marketed
Conversion to Once-daily Tacrolimus Conversion to Once-daily Tacrolimus marketed
Mycophenolate mofetil Tab./Cap. Mycophenolate mofetil Tab./Cap. marketed Immunosuppressant; IMPDH inhibitor Inosine monophosphate dehydrogenase (IMPDH) type II Immunology; Transplantation
Baraclude Tab. 0.5mg Baraclude Tab. 0.5mg marketed
empagliflozin 10mg empagliflozin 10mg marketed
Eupasidin-s Tab Eupasidin-s Tab marketed
Imotun Imotun marketed Biological modulator Specific signaling molecules Other
EsoDuo® Tablet EsoDuo® Tablet marketed
Mycophenolate mofetil Tablet/Capsule Mycophenolate mofetil Tablet/Capsule marketed Inosine monophosphate dehydrogenase (IMPDH) inhibitor; immunosuppressant IMPDH type II (inosine monophosphate dehydrogenase) Immunology; Transplantation
Tacrolimus cap. Tacrolimus cap. marketed
Myreptic-N Tablet Myreptic-N Tablet marketed
Tacrolimus with Methotrexate Tacrolimus with Methotrexate marketed

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Novartis · 6 shared drug classes
  2. Hoffmann-La Roche · 5 shared drug classes
  3. Sanofi · 4 shared drug classes
  4. Hanmi Pharmaceutical Company Limited · 4 shared drug classes
  5. GlaxoSmithKline · 4 shared drug classes
  6. Pfizer · 4 shared drug classes
  7. Organon and Co · 4 shared drug classes
  8. AstraZeneca · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Chong Kun Dang Pharmaceutical:

Cite this brief

Drug Landscape (2026). Chong Kun Dang Pharmaceutical — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/chong-kun-dang-pharmaceutical. Accessed 2026-05-16.

Related